TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Diet and Migraine Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* overweight or obese (BMI between 25 and 42)~* women~* \>18 years and \< 50 years old~* Migraine meeting ICHD criteria for at least 6 months prior to screening~* headache frequency documented \> 2 and \< 10 headache days per month~* BP inclusion criteria are SBP \<160 or DBP \<100 mm Hg~Exclusion Criteria:~* hypocaloric diet (must be weight stable for prior 3 months)~* Self-report of alcohol or substance abuse in the past year or current treatment~* Type 1 or 2 diabetes

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Obese migraineurs (Type: OTHER): Low carbohydrate diet
- low-fat diet (Type: OTHER): Obese Migraineurs
- Controls (Type: OTHER): Controls receiving AHA diet recommendations

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Type I hyperlipoproteinemia.~* Fasting serum triglyceride levels of greater than 1000 mg/dL.~* Age \> 12 years~Exclusion Criteria:~* Secondary hypertriglyceridemias due to diabetes, renal disease, hypothyroidism, alcoholism and drug therapy such as estrogens and estrogen analogues, steroids, HIV-protease inhibitors, retinoic acid derivatives and interferons.~* Pregnant or lactating women~* Significant liver disease (elevated transaminases \> 2 times upper limit of normal)~* Alcohol abuse (\> 7 drinks or 84 g per week for women and \> 14 drinks for men or 168 g per week for men)~* Drug use (cocaine, marijuana, LSD, etc.)~* Major surgery in the past three months~* Congestive heart failure~* Serum creatinine greater than 2.5 mg/dL~* Cancer within the past five years~* Gastrointestinal surgery in the past~* Current therapy with anti-coagulants, digoxin and anti-arrhythmics~* Chronic malabsorption syndromes~* Cholestasis~* Acute illnesses such as acute pancreatitis in the last 8 weeks

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- SLx-4090 placebo/Orlistat Placebo (Type: PLACEBO_COMPARATOR): Slx-4090(placebo) is dosed as 4 tablets of 50 mg, three times per day with meals.~Orlistat (placebo) is dosed as 2 capsules of 60 mg, three times per day with meals.~This trial is adaptive design/flexible design. The participants were either randomized from the start of the study or after the completion of each treatment.
- Orlistat/placebo (Type: EXPERIMENTAL): Orlistat two capsules 60mg each, three times per day with meals. Placebo for SLx-4090, 4 tablets 50mg each, three times per day with meals. This trial is adaptive design/flexible design. The participants were either randomized from the start of the study or after the completion of each treatment.
- Orlistat placebo /SLx-4090 (Type: EXPERIMENTAL): Orlistat placebo 2 capsules, 60mg each three times per day with meals. Slx-4090 4 tablets, 50mg each. three times per day with meals. This trial is adaptive design/flexible design. The participants were either randomized from the start of the study or after the completion of each treatment.
- Orlistat/SLx-4090 (Type: EXPERIMENTAL): Orlistat, 2 capsules 60 mg each, three times per day with meals. SLx-4090 4 tablets 50mg each, three times per day with meals. This trial is adaptive design/flexible design. The participants were either randomized from the start of the study or after the completion of each treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Implications of Anesthetics on Sleep Consolidation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Primary Inclusion Criteria for Healthy volunteers~* Age between 18-35~* Native English speaking~* No hearing or speech difficulties~* No psychiatric, neurologic, or sleep disorders~* No chronic medical conditions, as reflected below under Primary Exclusion Criteria and above in 'Medical History'~* Non-smokers (within 3 months)~* Non-users of recreational or illicit drugs (including marijuana)~* Must be willing and able to pass the drug tests (no psychoactive substances), no ingestion of alcohol or sleep-altering drugs for the 48 hours prior to the study session.~* Normal weight~Primary Exclusion Criteria for Healthy volunteers~* Speech difficulties/disorders~* Hearing difficulties (including occluded or infected ear canals)~* Current hairstyles that do not allow the high-density EEG cap to make contact with the scalp (e.g., individuals with hair extensions, braids, dreadlocks or hairstyles that restrict the ability of electrodes to touch the scalp)~* Metal on/in/near their heads (including jewelry) that cannot be removed for the duration of the study~* Metal implants~* Serious abusers of alcohol or caffeine.~* Existing or suspected psychological or neurological disorders~* Pregnancy or suspected pregnancy (urine pregnancy test at visit 2)~* Chronic or transient (e.g., jet lag) problems with sleep; suspected sleep disorder~* Abnormal sleep habits, such as:~  * Sleeping less than 5 hours each night~ * Going to sleep before 8:00 PM or after 2:00 AM on a regular basis~ * Waking up before 5:00 AM or after 10:00 AM on a regular basis.~* Currently taking medications that regulate blood pressure; a history of high blood pressure, diabetes or stroke~* Chronic smokers~* Current use of aspirin, or other medications which increase bleeding, prior to the study session.~* Known drug allergies to anesthetics or a history of an adverse reaction to anesthesia.~* Known allergy to adhesives or electrode gel~* Medication that alters sleep, cognitive function, or both

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Dexmedetomidine Arm (Type: EXPERIMENTAL): Dexmedetomidine: Administration of a 0.5 mcg/kg bolus followed by an infusion of 0.5-0.7 mcg/kg/hr, titrated up by 0.1 mcg every 1 minute until the subject spontaneously closes his or her eyes. When the subject spontaneously closes his or her eyes the infusion continues for 90 minutes from that point.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Cancer-associated Anorexia Using Megestrol Acetate Concentrated Suspension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Cancer of multiple types in stage II, III, or IV and not a candidate for chemotherapy; but may have been receiving radiation therapy~* Fair, poor, or very poor appetite~* Cancer-associated anorexia/cachexia (documented weight loss of 2% over the prior week, or at least 5% within past 30 days, or at least 7.5% over prior 3 months, or at least 10% over prior 6 months)~* Weight loss perceived to be associated with diminished appetite~* Eastern Cooperative Oncology Group Performance score of 0, 1, or 2~* Life expectancy greater than 3 months~* Alert and mentally competent to complete study assessments~* Women of child-bearing potential required to use an adequate and reliable method of contraception. Post-menopausal women have to have been so for at least 1 year~* Screening laboratory values must not be clinically significant (some exceptions per protocol)~Exclusion Criteria:~* Brain, or head and neck tumors that may interfere with food consumption~* AIDS-related wasting~* Radiation therapy to head and neck, abdomen, or pelvis within past 6 weeks, or for whom radiation therapy is anticipated during the study such that the result may interfere with food consumption~* Presence of conditions that interfere with oral intake or ability to swallow~* Absence of normally functioning gut~* Known mechanical obstruction of the alimentary or biliary tract, or malabsorption syndrome~* Intractable or frequent vomiting~* Clinically significant diarrhea~* History of thromboembolic events, or on long-term anticoagulation for thromboembolism~* Uncontrolled diabetes mellitus, or symptomatic hypoadrenalism~* Poorly controlled hypertension or congestive heart failure~* Pregnant/lactating females, or planning on becoming pregnant~* Use of appetite stimulants within past 30 days~* Use of parenteral nutrition or tube feedings within past 1 week~* Chronic use of steroids within past 3 months (intermittent short-term use allowed)~* Current use of illicit substances~* Allergy, hypersensitivity, or other contraindication to megestrol acetate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Megestrol acetate concentrated suspension 110 mg/mL
- 2 (Type: ACTIVE_COMPARATOR): Megestrol acetate concentrated suspension 60 mg/mL
- 3 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Trial: Pain Management After Pectus Excavatum Repair, Epidural Versus PCA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing a pectus excavatum repair with bar placement.~* Pectus patients between 12 and 17.9 years of age.~Exclusion Criteria:~* Open repair~* Re-Do operation~* Known allergy to a pain medication in the protocol~* Existing contraindications to epidural catheter placement~* Requirement for 2 bars to be placed (rare)

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- PCA pain control (Type: ACTIVE_COMPARATOR): Patients will have PCA for pain control
- Epidural pain control (Type: ACTIVE_COMPARATOR): Patients will have an epidural for pain control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosis of RA \>/= 3 months duration.~* Continuous treatment of MTX 10 - 25 mg/week (or per local labeling requirements if the dose range differs) for at least 12 weeks before screening visit and on a stable dose for 8 weeks before screening visit.~* Active disease defined as: at least 6/66 swollen and 8/68 tender joints and high sensitivity C-reactive protein \> 10 mg/L.~Exclusion criteria:~* Age \< 18 years.~* Use of parenteral corticosteroids or intra-articular corticosteroids within 4 weeks of the screening visit.~* Use of oral corticosteroids in a dose higher than prednisone 10 mg or equivalent per day, or a change in dosage within 4 weeks of the screening visit.~* Prior treatment with a tumor necrosis factor (TNF)-alpha inhibitor, or other biological disease modifying anti-rheumatoid drug (DMARD) or Janus Kinase inhibitor.~* New treatment with or dose-adjustment of on-going nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclo-oxygenase-2 (COX-2) inhibitors within 4 weeks of the screening visit.~* Treatment with traditional oral DMARD /immunosuppressive agents other than MTX within 4 weeks or 12 weeks before the screening visit, depending on DMARD.~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab Open Label run-in (Type: EXPERIMENTAL): Adalimumab 40 mg every 2 weeks (Q2W) for 16 weeks added to stable dose of MTX.
- Etanercept + MTX (Randomized) (Type: ACTIVE_COMPARATOR): Etanercept 50 mg in combination with Placebo for sarilumab Q2W and etanercept 50 mg on alternating weeks for 24 weeks added to stable dose of MTX.
- Sarilumab 150 mg + MTX (Randomized) (Type: EXPERIMENTAL): Sarilumab 150 mg in combination with placebo for etanercept Q2W and placebo for etanercept on alternating weeks for 24 weeks added to stable dose of MTX.
- Sarilumab 200 mg + MTX (Randomized) (Type: EXPERIMENTAL): Sarilumab 200 mg in combination with placebo for etanercept Q2W and placebo for etanercept on alternating weeks for 24 weeks added to stable dose of MTX.
- Sarilumab 150 mg + MTX Open Label Sub-study (Type: EXPERIMENTAL): Sarilumab 150 mg Q2W for 52 weeks added to stable dose of MTX.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Contrast Enhanced Ultrasound vs. Computed Tomographic Angiography in the Detection of Endoleaks Following AAA Repair

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years old and greater~* Men or postmenopausal/non-pregnant women~* Abdominal aortic aneurysm successfully repaired by endograft deployment~* Creatinine \< 2.0 mL~* Planned CTA follow-up~Exclusion Criteria:~* Subjects with known or suspected hypersensitivity to blood, blood products, or albumin.~* Subjects unable/unwilling to give informed consent~* Unable to complete post-operative imaging studies~* Subjects identified to have a cardiac shunt by TTE~* Subjects with hepatic or respiratory disease~* Nursing mothers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Endoleak imaging (Type: OTHER): In the single arm all participants are recieving both imaging techniques; CEUS and CTA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of the Addition of Alanyl-Glutamine-Dipeptide to Dialysis Solution in Peritoneal Dialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent prior to any study-mandated procedure~* Male and female patients aged ≥ 19 years old~* Chronic renal failure; 2 months stable on PD~* no peritonitis within the previous 2 months~* Without severe concomitant disease~* Negative pregnancy test in female patients of childbearing potential and adequate contraception in female patients of childbearing age~Exclusion Criteria:~* Known hypersensitivity to study medication~* Treatment with another investigational drug within 1 month prior to start of study medication~* Malignancy requiring chemotherapy or radiation~* Pregnancy or nursing,~* Presumed non-compliance~* Limited efficacy of peritoneal dialysis due to anatomical anomalies or severe intra-abdominal adhesions~* Clinical significant inflammatory parameters~* Less than 50 kg body weight~* Immunosuppressive therapy

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: OTHER): Arm A includes 14 patients. In treatment period 1, arm A receives standard PDF with the interventional drug alanyl-glutamine-dipeptide as add-on. As it is a cross-over study design, in treatment period 2, group A receives standard PDF without add-on.
- Arm B (Type: OTHER): Arm B includes 14 patients who in treatment period 1 receive standard PDF without the investigational drug. As it is a cross-over study design, in treatment period 2 arm B receives standard PDF with alanyl-glutamine-dipeptide as add-on.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults greater than or equal to (≥) 18 years of age~* Curatively treated head and neck squamous cell cancer with T3-T4 and/or N2-N3 pathology, with or without other findings of poor prognosis such as extranodal extension, positive resection margins, and perineural or vascular involvement~* Eastern Cooperative Oncology Group (ECOG) status of 0 to 2~Exclusion Criteria:~* Macroscopic residual disease after surgery~* Previous treatment with anti-epidermal growth factor receptor (anti-EGFR) targeted therapies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erlotinib (Type: EXPERIMENTAL): Participants treated with surgical resection and chemoradiotherapy or radiotherapy alone will receive erlotinib tablets as 150 mg PO daily for 1 year until disease progression or intolerable toxicity.
- Placebo (Type: PLACEBO_COMPARATOR): Participants treated with surgical resection and chemoradiotherapy or radiotherapy alone will receive placebo treatment for 1 year until disease progression or intolerable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Risedronate in Patients With Painful Periprosthetic Resorption of the Hip Prothesis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects, 18 years of age or older.~* Written informed consent~* Subjects with cemented or not cemented total hip prothesis (for primitive or secondary coxarthrosis)~* Painful aseptic loosening~* Subject has pain 4 or greater on a 10 point Visual Pain Rating scale~* For subject woman of reproductive age, they must use reliable method(s) of contraception and/or abstinence, for the duration of therapeutic product exposure.~Exclusion Criteria:~* Subjects with septic loosening of hip prosthesis~  . Subjects with bilateral disease~* Subjects with implant mobility associated with pre-operative and intraoperative loosening~* Subjects under anti-osteoporotic treatment~* Subjects having stopped a biphosphonate traetment for less than one year~* Subjects with known allergy or sensitivity to any of the components in the study medication.~  * Subjects with Hypocalcemia~ * Females who are pregnant, breast-feeding, or planning a pregnancy during the study or who think that they may be pregnant at the start of the study, or females of childbearing potential who are unable or unwilling to use a reliable form of contraception during the study.~ * Subjects with severe kidney failure ( creatinine \< 30 ml/min)).~ * Subjects participation in another research study~ * Subjects with previous osteonecrosis of the jaw

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Risedronate (Type: EXPERIMENTAL): Patients take an oral tablet of Risedronate 75 mg, 2 consecutive days per month during 18 months.
- Placebo (Type: PLACEBO_COMPARATOR): Patients take an oral tablet of Placebo, 2 consecutive days per month during 18 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Zoledronic Acid in Acute Spinal Cord Injury: Prevention of Bone Loss

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women~2. Age 18 years and older~3. Spinal cord injury within 8 weeks of study entry~4. ASIA AIS A or B~5. Medically stable in the opinion of their physiatrist~6. Able to have dexa performed~7. Able to return for follow-up at 6 and 12 months~Exclusion Criteria:~1. Vitamin D deficiency~2. Hypocalcemia~3. Renal insufficiency (estimated creatinine clearance \<30ml/min)~4. Abnormal thyroid hormone status~5. Abnormal mental status~6. Osteoporosis at the hip or spine by dexa

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- zoledronic acid (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues